ArticleClinics (Sao Paulo, Brazil)2026
Dapagliflozin as an adjunct to insulin improves glycemic control, weight, and lipid profile with a superior safety profile in type 2 diabetes: a randomized trial.
Lili Sun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.